Adult Indications

Adult GHD

About Adult Growth Hormone Deficiency (GHD)

In 1996, Humatrope was the first growth hormone therapy to receive FDA approval for adult GHD treatment. Humatrope is approved for replacement of endogenous growth hormone in adults with growth hormone deficiency who meet either of the following two criteria:

• Adult-onset growth hormone deficiency (AO GHD) – patients who have growth hormone deficiency, either alone or accompanied by multiple hormone deficiencies (hypopituitarism), as a result of hypothalamic disease, pituitary disease, surgery, radiation therapy, or trauma;
  
  OR
  
  
• Childhood-onset growth hormone deficiency (CO GHD) – patients who were growth hormone deficient during childhood, and who have growth hormone deficiency confirmed as an adult before replacement therapy with Humatrope is started.

Humatrope can help you successfully treat your adult patients with GHD. Click on these links to view and print pdfs of the:

• Adult Endocrinology Health Care Professional Handbook
• Adult Patient Hypopituitarism Handbook
• Tools for Evaluation of Quality of Life
  • Questions on Life Satisfaction-Hypopituitarism© (QLS-H)©
  • QLS-H Patient Letter

  What's missing?

  • Adults with GHD often present with multiple metabolic abnormalities.
  • GHD is linked to a number of risk factors for cardiovascular disease.
  • Adults with GHD may also suffer from substantially impaired quality of life.

  Does this list of questions describe your adult patients?

  • Do they often feel tired and lack energy?
  • Do they experience a decrease in ability to exercise?
  • Are they unhappy with the way they look?
  • Has their social interaction decreased?
  • Do they feel isolated?

  Humatrope therapy may be the missing piece

  • For more information about the "whole puzzle" of Humatrope therapy for adult GHD, click on this link to view and print a pdf of the Adult Endocrinology Health Care Professional Handbook.